Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Winter;15(1):84-8.
doi: 10.1111/j.1755-5949.2008.00071.x.

The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD)

George A Fraser  1
Affiliations

The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD)

George A Fraser. CNS Neurosci Ther. 2009 Winter.

Abstract

This is the report of an open label clinical trial to evaluate the effects of nabilone, an endocannabinoid receptor agonist, on treatment-resistant nightmares in patients diagnosed with posttraumatic stress disorder (PTSD).

Methods: Charts of 47 patients diagnosed with PTSD and having continuing nightmares in spite of conventional antidepressants and hypnotics were reviewed after adjunctive treatment with nabilone was initiated. These patients had been referred to a psychiatric specialist outpatient clinic between 2004 and 2006. The majority of patients (72%) receiving nabilone experienced either cessation of nightmares or a significant reduction in nightmare intensity. Subjective improvement in sleep time, the quality of sleep, and the reduction of daytime flashbacks and nightsweats were also noted by some patients. The results of this study indicate the potential benefits of nabilone, a synthetic cannabinoid, in patients with PTSD experiencing poor control of nightmares with standard pharmacotherapy. This is the first report of the use of nabilone (Cesamet; Valeant Canada, Ltd., Montreal, Canada) for the management of treatment-resistant nightmares in PTSD.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Diagnostic and statistical manual of mental disorders, DSM‐IV‐TR. Washington , DC : American Psychiatric Association, 2000.
    1. Kessler R, Sonnega A, Bromet E, Hughes M, Nelson CB. Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1995;52:1048–1060. - PubMed
    1. Van Ameringen M. Posttraumatic Stress Disorder in Canada. CNS Neurosci & Ther 2009; in press. - PMC - PubMed
    1. Clinical practice guidelines. Management of anxiety disorders. Can J Psychiatry 2006;51(Suppl. 2):57S–62S. - PubMed
    1. Friedman, M . Post‐traumatic and acute stress disorders: The latest assessment and treatment strategies, 4th Edition. Kansas City: Compact Clinicals, 2006; 58–64.